Nuvectra Corp (NASDAQ:NVTR) shares gapped down before the market opened on Thursday . The stock had previously closed at $2.43, but opened at $1.39. Nuvectra shares last traded at $0.22, with a volume of 12,910,300 shares.
Several analysts have recently issued reports on the company. ValuEngine downgraded Nuvectra from a “hold” rating to a “sell” rating in a research note on Thursday. Raymond James downgraded Nuvectra from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Zacks Investment Research downgraded Nuvectra from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Piper Jaffray Companies decreased their price target on Nuvectra from $18.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Finally, JMP Securities decreased their price target on Nuvectra to $10.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $8.75.
The company has a current ratio of 4.86, a quick ratio of 4.42 and a debt-to-equity ratio of 0.58. The firm has a market cap of $23.52 million, a price-to-earnings ratio of -0.07 and a beta of 0.69. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $2.74.
About Nuvectra (NASDAQ:NVTR)
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Featured Story: Futures Contract
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.